Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects

Clinical Chemistry

Volumn 43, Issue 1, 1997, Pages 13-17

  Hong, Seung Ho ^a   Park, Woo Hyun ^a   Lee, Chung Choo ^a   Song, Jung Han ^b   Kim, Jin Q ^c  

^a Seoul National University   (South Korea)

^b Dankook University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

allele frequency; atherosclerosis; hypertriglyceridemia; restriction fragment length polymorphism

Indexed keywords

APOLIPOPROTEIN A1;

ADULT; ARTICLE; ATHEROSCLEROSIS; CAUCASIAN; FEMALE; GENETIC VARIABILITY; HUMAN; HYPERTRIGLYCERIDEMIA; KOREA; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0004362463     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.1.13     Document Type: Article

References (37)

1. Fielding CJ, Shore VG, Fielding PE. A protein cofactor of lecithin: cholesterol acyltransferase. Biochem Biophys Res Commun 1972;46:1493-8.
2. Steinmetz A, Utermann G. Activation of lecithin:cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem 1985;260:2258-64.
3. Karathanasis SK. Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, AIV genes. Proc Natl Acad Sci U S A 1985;82:6374-8.
4. Humphries SE. DNA polymorphism of the apolipoprotein genestheir use in the investigation of the genetic component of hyperlipidemia and atherosclerosis. Atherosclerosis 1988;72:89-108.
5. Lusis AJ. Genetic factors affecting blood lipoproteins: the candidate gene approach. J Lipid Res 1988;29:397-429.
6. Humphries S, Paul H, Jeenah M, Rosseneu M, Miller N. The contribution of variation at the apo AI-CIII-AIV gene locus to the determination of HDL-cholesterol and apo AI levels. In: Carlson L, ed. Disorders of HDL metabolism. London: Smith-Gordon, 1990:63-70.
7. Humphries S, Paul-Hayase H, Gudnason V, Rosseneu M, Dunning A, Talmud P. Identification of common genetic polymorphisms that determine plasma levels of LDL and HDL. In: Stein O, Eisenberg S, Stein Y, eds. Atherosclerosis IX. Proceedings of the Ninth Symposium on Atherosclerosis, Chicago, IL, October 6-11. 1991:255-60.
8. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE. DNA polymorphism adjacent to human apoprotein A-I gene-relation to hypertriglyceridaemia. Lancet 1983;i:444-6.
9. Rees A, Sharpe C, Stocks J, Vella MA, Shoulders CC, Katz, et al. DNA polymorphism in the apo AI-CIII gene cluster association with hypertriglyceridemia. J Clin Invest 1985;76:1090-5.
10. Shoulders CC, Ball MJ, Mann JI, Baralle FE. Genetic marker in apolipoprotein AI/CIII gene complex associated with hypercholesterolemia. Lancet 1986;ii:1286-8.
11. Shoulders CC, Ball MJ, Baralle FE. Variation of the apo AI/CIII/AIV gene complex: its association with hyperlipidaemia. Atherosclerosis 1989;80:111-8.
12. Aalto-Setala K, Kontula K, Sane T, Nieminen M, Nikkila E. DNA polymorphisms of apolipoprotein AI/CIII and insulin genes in familial hypertriglyceridemia and in coronary heart disease. Atherosclerosis 1987;66:145-52.
13. Henderson HE, Landon SV, Michie J, Berger MB. Association of a DNA polymorphism in the apolipoprotein CIII gene with diverse hyperlipidaemic phenotypes. Hum Genet 1987;75:62-5.
14. Ferns GAA, Stocks J, Ritchie C, Galton DJ. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction. Lancet 1985;ii:300-3.
15. Deeb S, Failor A, Brown BG, Brunzell JD, Albers JJ, Motulsky AG. Molecular genetics of apolipoproteins and coronary heart disease. Cold Spring Harbor Symp Quant Biol 1986;51:403-9.
16. Price WH, Morris SW, Kitchin AH, Wenham PR, Burgon PR, Donald PM. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. Lancet 1989;i:1407-11.
17. Hayden MR, Kirk H, Clark C, Frohlich J, Rabkin S, Mcleod R, Hewitt J. DNA polymorphisms in and around the apo-AI-CIII genes and genetic hyperlipidemias. Am J Hum Genet 1987;40:421-30.
18. Wojciechowski AP, Farrall M, Cullen P, Wilson TME, Bayliss JD, Farren B, et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24. Nature 1991;349:161-4.
19. Kessling AM, Berg J, Mockleby E, Humphries SE. DNA polymorphism around the apo AI gene in normal and hyperlipidaemic individuals selected for a twin study. Clin Genet 1986;29:485-90.
20. Paulweber B, Friedl W, Krempler F, Humphries SE, Sandhofer F. Genetic variation in the apolipoprotein AI-CIII-AIV gene cluster and coronary heart disease. Atherosclerosis 1988;73:125-33.
21. Wile DB, Barbir M, Gallagher J, Myant NB, Ritchie CD, Thompson GR, Humphries SE. Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apo AI and HDL-cholesterol concentration. Atherosclerosis 1989;78:9-18.
22. Ordovas JM, Schaefer EJ, Salem D, Ward RH, Glueek CJ, Vergani C, et al. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med 1986;413:617-27.
23. Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE. Human apolipoprotein A-I gene promoter polymorphism: Association with hyperalphalipoproteinemia. J Lipid Res 1990;31:1371-7.
24. Jeenah M, Kessling A, Miller N, Humphries S. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990;7:233-41.
25. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet 1995;95:371-5.
26. Saha N, Tay JSH, Low PS, Basair J, Hong S. Rve restriction fragment length polymorphisms of the apo A1-C3 gene and their influence on lipids and apolipoproteins in healthy Chinese. Hum Hered 1995;45:303-10.
27. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning - a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:9.14-9.23.
28. Needham EWA, Mattu RK, Rees A, Stocks J, Gallon DJ. A polymorphism in the human apolipoprotein AI promoter region: a study in hypertriglyceridemic patients. Hum Hered 1994;44:94-9.
29. Paul-Hayase, Rosseneu M, Robinson D, Van Bervliet JP, Deslypere JP, Humphries SE. Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum Genet 1992;88:439-46.
30. Tenkanen H, Koskinen P, Metso J, Baumann M, Lukka M, Kauppinen-Makelin R, et al. A novel polymorphism of apolipoprotein A-IV is the result of an asparagine to serine substitution at residue 127. Biochim Biophys Acta 1992;1138:27-33.
31. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975;98:503-7.
32. Hill WG, Robertson A. Linkage disequilibrium of finite populations. Theor Appr Genet 1968;38:226-31.
33. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249:790-3.
34. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A 1993;90:4562-6.
35. Li WW, Dammerman M, Smith JD, Metzger S, Breslow JL, Left T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995;96:1601-5.
36. Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest 1992;89:1796-800.
37. Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994;35:1292-6.